Alexion Soliris Could Reach Market By Q1 2007 For Orphan Blood Disorder
This article was originally published in The Pink Sheet Daily
Announcement of BLA submission coincides with publication of pivotal data in the New England Journal of Medicine.
You may also be interested in...
The company will await final data from the 12-month SHEPHERD study to submit eculizumab for paroxysmal noctural hemoglobinuria.
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.